Physician profile
Mohamed E Taha
NPI 1407217300
$7,722.57
in general payments reported to CMS, 2019-2025
19 companies · $1,008 in 2025
The $1,008 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.31 · 2021: $1,248 · 2022: $1,423 · 2023: $3,112 · 2024: $907 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110 · Grant: $1,398 · Travel and Lodging: $1,161 · Education: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,109.77 |
| Grant | $1,398.17 |
| Travel and Lodging | $1,160.73 |
| Education | $358.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,405.91 | 2021-2025 | Onyx Frontier, Symplicity G3 |
| Abbott Laboratories | $1,524.85 | 2021-2025 | Diamondback Coronary, Cardiomems |
| Boston Scientific Corporation | $1,398.17 | 2023 | |
| Abiomed | $611.16 | 2022-2025 | Impella |
| Shockwave Medical, INC | $477.30 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $305.35 | 2021-2025 | Lifevest |
| Chiesi USA, INC. | $263.36 | 2023-2024 | Kengreal |
| Edwards Lifesciences Corporation | $179.75 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $131.22 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $105.05 | 2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.33 | 2025 | Jardiance |
| Scpharmaceuticals INC. | $57.97 | 2025 | |
| Novo Nordisk INC | $48.94 | 2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $40.07 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $32.07 | 2025 | Opsumit, Uptravi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24.31 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $19.06 | 2025 | Camzyos |
| Xeris Pharmaceuticals, INC. | $18.42 | 2025 | Keveyis |
| Ge Healthcare | $17.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Taha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.